Dr. Reddy’s wins generic Zantac approval
This article was originally published in The Tan Sheet
Executive Summary
FDA approves Dr. Reddy's Laboratories abbreviated new drug application to manufacture and market generic OTC versions of ranitidine 150 mg tablets acid indigestion treatment (GlaxoSmithKline's Zantac), Dr. Reddy's announces Sept. 13. The Hyderabad, India-based drug firm says the approval marks its first U.S. drug approval since it unveiled plans in May to launch a store-brand OTC business unit in the country. The firm is set to expand its OTC product portfolio and additional product introductions in the coming months which will include Rx switches and select OTC monograph products, the firm's North American Generics President Mark Hartman said...
You may also be interested in...
Perrigo's Zantac 150 Generic Marks First Approval From Remediated Plant
Perrigo will launch private-label equivalents of OTC heartburn reliever Zantac 150 this summer.
FDA in India
HHS Secretary Michael Leavitt and FDA Commissioner Andrew von Eschenbach are organizing teams to help advise the Indian government in creating its equivalent to FDA, Leavitt says Jan. 7 in a post to his blog. Leavitt offered the Indian Minister of Health and Family Welfare, Anbumani Ramadoss, technical assistance and discussed food and drug safety, he says. In September 2007, von Eschenbach worked with Chinese officials to finalize a memorandum on food, drug and medical device safety (1"The Tan Sheet" Sept. 24, 2007, In Brief)...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.